News

Public · Published

Krystal Biotech Is Maintained at Buy by TD Cowen

TD Cowen maintained a Buy rating on Krystal Biotech while cutting its price target to $380.00 per share from $403.00 per share.

Published:

Updated:

What happened

TD Cowen maintained a Buy rating on Krystal Biotech while cutting its price target to $380.00 per share from $403.00 per share.

Confirmed

Global impact / market context

A lower price target means the analyst still expects gains but a smaller upside than before. Investors often read this as slightly reduced confidence in future growth, even though the Buy rating itself was kept unchanged.

Analyst inference

Sell-side price targets are estimates of where a stock could trade, not guarantees. A cut alongside a maintained Buy rating suggests a modest reassessment of value rather than a changed view on the company's prospects.

Analyst inference

What to watch

  1. Whether other analysts follow TD Cowen in lowering their price targets for Krystal Biotech, which would signal broader expectations of slower growth. Confirmed
  2. Future analyst reports could raise the price target again if company results beat expectations, which would reverse the direction of this revision. Proposed
  3. Watch the gap between the $380 target and the current share price, since a narrow gap could mean less upside priced in for investors. Analyst inference

Evidence

  • Original source link unavailable